Schering-Plough and Merck's cholesterol drug Vytorin doesn't lower the risk of major heart valve problems and need for related surgical procedures, according to a large-scale study.
The drug was no better than placebo at lowering a the risk of major cardiovascular events, compared with placebo, in patients suffering from a condition that blocks blood flow to part of the heart. The study, called SEAS, involved 1,873 patients spread throughout several countries.
Vytorin also failed to meet one of its two secondary goals, which both involved reducing certain types of heart problems.
There were also more cancer deaths for patients taking Vytorin, though the study said that data is based on a small number of people and could have occurred by chance.